MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

Core Insights - MediciNova, Inc. has completed patient enrollment for its Phase 2 clinical trial, MN-001-NATG-202, which is evaluating MN-001 (Tipelukast) for treating hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) associated with Type 2 diabetes (T2DM) [1][2] Group 1: Clinical Trial Details - The MN-001-NATG-202 study is a multi-center, randomized, double-blind, placebo-controlled trial with a 1:1 randomization to receive either 500 mg/day of MN-001 or placebo for 24 weeks [2] - Co-primary endpoints include changes in liver fat content measured by controlled attenuation parameter (CAP) score and fasting serum triglycerides at Week 24 [2] - Top-line data from the trial is expected by summer 2026 [2] Group 2: About MN-001 - MN-001 (Tipelukast) is a novel, orally bioavailable small molecule that exhibits anti-inflammatory and anti-fibrotic activity through multiple mechanisms, including leukotriene receptor antagonism and inhibition of phosphodiesterase [3] - The compound has shown potential in down-regulating genes that promote fibrosis and inflammation, as well as inhibiting triglyceride synthesis in hepatocytes [3] Group 3: Disease Context - Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance, which contributes to dyslipidemia, including hypertriglyceridemia and hypercholesterolemia, increasing the risk of cardiovascular complications and liver-related conditions like NAFLD [4] - NAFLD is frequently associated with T2DM and dyslipidemia, highlighting the importance of addressing lipid abnormalities in these patients [4] Group 4: Company Overview - MediciNova, Inc. is a clinical-stage biopharmaceutical company with a late-stage pipeline focused on developing novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases [5] - The company has 11 programs in clinical development, with its lead asset, MN-166 (Ibudilast), currently in Phase 3 trials for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) [5]